Abstract
Neuroendocrine secretory protein-55 (NESP-55) is a recently described member of the chromogranin family and appears to be a marker of the constitutive secretory pathway in certain neural, neuroendocrine, and endocrine cell types. It has been shown to be selectively expressed in tumors differentiating towards the adrenal chromaffin and pancreatic islet cell phenotypes. The highest levels of NESP-55 expression, at least in animals, appear to be in the adrenal medulla and the pituitary gland. However, very little is known about the status of NESP-55 expression in pituitary adenomas. We therefore studied the immunohistochemical profile of NESP-55 expression in a series of 30 well-characterized pituitary adenomas (five each of FSH/LH and ACTH, four GH, three TSH, seven prolactin, and six null cells). All tumors were positive for one or more generic marker(s) (chromogranin A, synaptophysin, neuron-specific enolase) of neuroendocrine differentiation. All pituitary adenomas selected for study were stained for NESP-55 with appropriate positive and negative controls. NESP-55 immunoreactivity, seen as brown finely granular cytoplasmic staining of the tumor cells with prominent perinuclear accentuation, was graded as focal (<10% tumor cells staining), moderate (10–50% tumor cells staining), and diffuse (>50% tumor cell staining). Four of seven prolactinomas were positive for NESP-55 (one focal, two moderate, and one diffuse). Two of four GH adenomas were also positive (one focal and one diffuse) while only 1/5 FSH tumors showed a moderately intense immunoreactivity. All other pituitary adenomas were completely negative for NESP-55. Our results indicate that, in human pituitary adenomas, NESP-55 has a more restricted pattern of expression than that of chromogranins A and B. Since immunohistochemical expression of NESP-55 is largely confined to prolactinomas and GH adenomas, it raises the possibility that NESP-55 may somehow be involved in the secretory pathways of these specific cell types.
Similar content being viewed by others
References
Lovisetti-Scamihorn P, Fischer-Colbrie R, Leitner B, Scherzer G, Winkler H. Relative amounts and molecular forms of NESP-55 in various bovine tissues. Brain Res 1999; 829:2478–85.
Taupenot L, Harper KL, and O’Connor DT. The chromogranin–secretogranin family. N Engl J Med 2003; 348:1134–49.
Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H, Fischer-Colbrie R. Molecular cloning and characterization of NESP-55, a novel chromogranin like precursor of peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997; 272:11657–11662.
Fischer-Colbrie R, Laslop A, Kirchmair R. Secretrogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol.1995; 46:49–70.
Winkler H, Fischer-Colbrie R. The chromogranin A and B: The first 25 years and future perspectives. Neuroscience 1992; 49:497–528.
Winkler H. The functional role of Chromogranins (Chromogranin A and B, Secretogranin II and 7B2). Pergamon, Oxford. (Ed) 1996.
Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin: A novel pancreatic peptide that inhibits insulin secretion. Nature. 1986; 324:476–78.
Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extra cellular calcium in isolated segments of human blood vessels. Reg Pep 1992; 41:9–18.
Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Palmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100:1623–1633.
Strub JM, Garcia-Sablone P, Lonning K, Taupenot P, Hubert A, Van Dorsselaer A, Aunis D, Metz-Boutigue M.H. Processing of chromogranin B in bovine adrenal medulla: Identification of secretolytin, the endogenous C-terminal fragment of residues 614–626 with antibacterial activity. Eur J Biochem 1995; 229:356–368
Agneter E, Sitte HH, Stöckl-Hiesleitner S, Fischer-Colbrie R, Winkler H, Singer EA. Sustained dopamine release induced by secretoneurin in the striatum of the rat, a micro dialysis study. J Neurochem 1995; 65:622–625.
Saria A, Troger J, Kirchmair R, Fischer-Colbrie R, Hogue-Angeletti R, Winkler H, Secretoneurin releases dopamine from rat striatal slices: A biological effect of a peptide derived from secretogranin II (chromogranin C) Neuroscience 1993; 54:1–4.
Kirchmair R., Gander R., Egger M., Hanley A., Silver M., Ritsch A., Murayama T., Kaneider N., Sturm W., Kearny M., Fischer-Colbrie R., Kircher B., Gaenzer H., Wiedermann C.J., Ropper A.H., Losordo D.W., Patsch J.R. and Schratzberger P. (2004) The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 109, 777–783.
Feldman SA, Eiden LE. The chromogranins: Their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 2003; 14:3–23.
Fahrenkamp AG, Wibbeke C, Winde G, Ofner D, Böcker W, Fischer-Colbrie R. Secretogranin II in neuroendocrine tumors of the gastrointestinal tract. Virchows Arch 1995; 426:361–715.
Weiler R, Fischer-Colbrie R, Schmid KW, et al. Immunological studies on occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 1988; 12:877–884.
Vallet Virginie S, Li Jacques Y, Jacques D. Secetogranin II (Sg II) distribution and processing studies in human normal and adenomatous anterior pituitaries using new polyclonal antibodies. Regul Pep 1997; 68:155–63
Srivastava A, Padilla O, Fischer-Colbrie R, Tischler AS, Dayal Y. Neuroendocrine secretary protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol 2004; 28:1371–78.
Hayward BE, Moran V, Strain L et al. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally and bidirectionally derived proteins. Proc Natl Acad Sci USA.1998; 95:15475–15480.
Eder S., Leierer J., Klimaschewski L., Wilhelm A., Volknandt W., Laslop A. and Fischer-Colbrie R. (2004) Secretion and molecular forms of NESP55, a novel genomically imprinted neuroendocrine-specific protein from AtT-20 cells. Neurosignals 13, 298–307.
Bastepe M., Frohlich L.F., Linglart A., Abu-Zahra H.S., Tojo K., Ward L.M. and Juppner H. (2005) Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat. Genet. 37, 25–27.
Li JY, Lovesetti-Scamihorn P, Fischer-Colbrie R, Winkler H, Dahlstrom A. Distribution and intramural trafficking of a novel member of the chromogranin family: NESP 55, in the rat peripheral nervous system. Neuroscience 2002; 110: 731–745.
Bauer R, Ischia R, Marksteiner J, Kapeller A, Fischer-Colbrie R. Localization of neuroendocrine protein 55 messenger RNA in the rat brain. Neuroscience 1999; 91:685–694.
Bauer R, Weiss C, Marksteiner J, Doblinger A, Fischer-Colbrie R, Laslop A. The new chromogranin- like protein NESP 55 is preferentially localized in adrenaline-synthesizing cells of the bovine and rat adrenal medulla. Neuroscience Lett 1999; 263:13–16.
Fischer-Colbrie, R Eder S, Lovisetti-Scamihorn P, Becker A, and Laslop A. Neuroendocrine secretary protein 55: A novel marker of the constitutive secretory pathway. Ann N Y Acad Sci 2002; 971:317–322
Jakobsen A-M, Ahlman H, Kolby L, Abrahamsson J, Fischer-Colbrie R, Nilsson O. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumors of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer 2003; 88:1746–54.
Schmid KW, Kröll M, Hittmair A, Maier H, Tötsch M, Gasser R, Finkenstett G, Houge-Angeletti R, Fischer-Colbrie R. Chromogranin A and B in adenoma of the pituitary. An immunohistochemical study of 42 cases. Am J Surg Pathol. 1991; 15:1072–1077.
Riva C, Leutner M, Capella C, Usellini L, la Rosa S, Brianza MR, Buffa R. Different expression of chromogranin A and B in various types of pituitary adenomas. Zentralbl Pathol 1993; 139:165–70.
Lloyd RV, Jin L. Analysis of chromogranin/secretogranin messenger RNAs in human pituitary adenomas. Diag Mol Pathol. 1994; 3:38–45.
Fischer-Colbrie R, Lassman H, Hagn C et al. Immunological studies on distribution of chromogranin A and B in endocrine and nervous tissues. Neuroscience 1985; 16:547–555.
Schmid KW, Fischer-Colbrie R, Hagn C et al. Chromogranin A and B and secretogranin II in medullary carcinoma of thyroid. Am J Surg Pathol.1987; 7:347–353.
Jin L, Chandler WF, Smart JB, England BG, Lloyd RV. Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression. J Clin Endocrinol Metab 1993; 76:728–35.
Rosa P, Bassetti M, Weiss U, Huttner WB. Widespread occurrence of chromogranins/secretogranins in the matrix of secretory granules of endocrinologically silent pituitary adenomas. J Histochem Cytochem 1992; 40:523–533.
Schmid KW, Kunk B, Kirchmair R, Tötsch M, Böcker W, Fischer-Colbrie R. Immunohistochemical detection of secretogranin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues. Histochem J 1995; 27:473–81.
Venetikou MS, Ghatei MA, Burrin JM, Latif S, Bloom SR. 7B2, a new protein secreted by human functionless pituitary tumors in vitro. Acta Endocrinol (Copen). 1988; 118:521–527.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gupta, M., Lloyd, R.V., Fischer-Colbrie, R. et al. Immunohistochemical Expression of Neuroendocrine Secretory Protein-55 (NESP-55) in Pituitary Adenomas. Endocr Pathol 22, 150–154 (2011). https://doi.org/10.1007/s12022-011-9162-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12022-011-9162-y